Clinical therapies have been established with vemurafenib, a selective inhibitor of BRAF (v-raf murine sarcoma viral oncogene homolog B) and dabrafenib in treating malignant melanoma, as well as non-small cell bronchial and thyroid carcinoma. This evidence concerns the gene BRAF and melanoma.